

## Human MAP7 siRNA

Catalogue No.: abx923487

siRNA to inhibit MAP7 expression using RNA interference.

This product is provided as three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

**Target:** MAP7

**Reactivity:** Human

**Tested Applications:** RNAi

**Host:** Synthetic

**Recommended dilutions:** Optimal dilutions/concentrations should be determined by the end user.

|    | Plate (wells) | Final Medium Volume (ml) | Final siRNA Concentration (nM) | 20 µM siRNA Volume (µl) | Lipofectamine 2000 Volume (µl) |
|----|---------------|--------------------------|--------------------------------|-------------------------|--------------------------------|
| 96 | 0.1           |                          | 100                            | 0.5                     | 0.25                           |
|    |               |                          | 50                             | 0.25                    | 0.25                           |
|    |               |                          | 10                             | 0.05                    | 0.25                           |
| 24 | 0.5           |                          | 100                            | 2.5                     | 1                              |
|    |               |                          | 50                             | 1.25                    | 1                              |
|    |               |                          | 10                             | 0.25                    | 1                              |
| 12 | 1             |                          | 100                            | 5                       | 2                              |
|    |               |                          | 50                             | 2.5                     | 2                              |
|    |               |                          | 10                             | 0.5                     | 2                              |
| 6  | 2             |                          | 100                            | 10                      | 5                              |
|    |               |                          | 50                             | 5                       | 5                              |
|    |               |                          | 10                             | 1                       | 5                              |

**Form:** Lyophilized

**Purity:** > 97%

**Quality Control:** Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

**Storage:** Shipped at 4 °C. Store at -20 °C for up to one year.

**UniProt Primary AC:** Q14244 ([UniProt](#), [ExpASY](#))

**Gene Symbol:** MAP7

# Datasheet

Version: 1.0.0  
Revision date: 01 Jul 2025



**GeneID:** [9053](#)

**NCBI Accession:** NM\_001198608.1

**KEGG:** hsa:9053

**Specificity:** MAP7 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

**Note:** This product is for research use only.

**Directions for use:**

1. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube.
2. Resuspend the siRNA oligos to an appropriate concentration with DEPC water (e.g. resuspend one vial of 5 nmol siRNA oligo in 250  $\mu$ l of DEPC water for a final concentration of 20  $\mu$ M).
3. Transfect with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis.

For Reference Only